AROPILO SR, 2 mg, prolonged-release tablets
AROPILO SR, 4 mg, prolonged-release tablets
AROPILO SR, 8 mg, prolonged-release tablets
Ropinirole
The active substance of AROPILO SR is ropinirole, which belongs to a group of medicines called dopamine agonists.
Dopamine agonists work in the brain in a similar way to a natural substance called dopamine.
AROPILO SR, prolonged-release tablets are used to treat Parkinson's disease.
In patients with Parkinson's disease, there is a low level of dopamine in some parts of the brain.
Ropinirole works in a similar way to natural dopamine in the brain, helping to alleviate the symptoms of Parkinson's disease.
Before starting to take AROPILO SR, you should discuss with your doctor or pharmacist:
if you are pregnant or think you may be pregnant
if you are breast-feeding
if you are under 18 years old
if you have severe heart disease
if you have severe mental health problems
if you have a history of particular tendencies and/or behaviors(see section 4)
if you have an intolerance to some sugars (e.g. lactose).
If you experience any of the following symptoms after stopping or reducing the dose of ropinirol, such as depression, apathy, anxiety, lack of energy, sweating, or pain(known as dopamine agonist withdrawal syndrome or DAWS), you should inform your doctor. If the symptoms persist for more than a few weeks, your doctor may decide to adjust the dose of the medicine.
You should inform your doctor if you or a family member notice that you have developed any of these behaviors or if you are unable to resist the impulse, drive, or temptation to perform certain activities that could harm you or others. This condition is called impulse control disorders and may include behaviors such as compulsive gambling, excessive eating, or spending, or an increased sexual drive or sexual thoughts. Your doctor may need to adjust the dose or stop the treatment.
You should contact your doctor if you or a family member notice any particular behaviorswhile taking AROPILO SR (such as uncontrollable gamblingor increased sexual drive and/or activity). Your doctor may need to adjust the dose or stop the treatment.
You should inform your doctorif you start or stop smoking while taking AROPILO SR. Your doctor may need to adjust the dose.
and about any medicines you plan to take, including those obtained without a prescription, herbal products, and other medicines available without a prescription.
You should remember to inform your doctoror pharmacist if you start taking any other medicine while taking AROPILO SR.
Some medicines may affect the action of ropinirol or increase the risk of side effects. Ropinirol may also affect the action of other medicines.
These medicines include:
fluvoxamine (an antidepressant)
medicines used for other mental health problems, such as sulpiride
HRT (hormone replacement therapy)
metoclopramide, which is used to treat nausea and heartburn
antibiotics ciprofloxacin and enoxacin
any other medicines used for Parkinson's disease.
You should inform your doctorif you are taking or have recently taken any of these medicines. You may need to have additional blood testsif you are taking any of these medicines with ropinirol:
AROPILO SR can be taken with or without food.
AROPILO SR is not recommended during pregnancy, unless your doctor considers that the benefits of taking the medicine outweigh the risks to the unborn baby. AROPILO SR is not recommended during breast-feeding, as it may affect milk production.
You should inform your doctor immediatelyif you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will also advise you if you are breast-feeding or plan to breast-feed.
AROPILO SR may cause drowsiness. Sudden sleepiness may occur, and sometimes sudden and unexpected episodes of sleep without warning.
While taking AROPILO SR, you may experience hallucinations (seeing, hearing, or feeling things that are not there). If you experience hallucinations, you should not drive or operate machinery.
If you suspect that you may experience these symptoms, do not drive, operate machinery, or perform activitieswhere drowsiness or falling asleep may put you or others at risk of serious injury or death. Do not perform such activities until the symptoms have resolved.
You should discuss this with your doctorif this is a problem for you.
If you have been told that you have an intolerance to some sugars, you should contact your doctor before taking the medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is essentially 'sodium-free'.
This medicine should always be taken exactly as advised by your doctor. If you are unsure, you should ask your doctor or pharmacist.
AROPILO SR should not be taken by children. AROPILO SR is not intended for use in patients under 18 years old.
AROPILO SR can be used to treat the symptoms of Parkinson's disease as a single medicine or in combination with another medicine called L-dopa (also known as levodopa). If you are taking L-dopa, you may experience involuntary movements (dyskinesias) when you start taking AROPILO SR. If you experience these symptoms, you should inform your doctor, who may need to adjust the doses of your medicines.
AROPILO SR tablets are designed to release the medicine slowly over a period of more than 24 hours. If, due to your condition (e.g. during diarrhea), the medicine passes through your body too quickly, the tablets may not dissolve completely and may not work as they should. You may see the tablets in your stool. In such a situation, you should contact your doctor as soon as possible.
It may take some time to find the right dose of AROPILO SR for you.
The recommended starting doseof AROPILO SR is 2 mg once daily for the first week. Your doctor may increase the dose to 4 mg once daily from the second week of treatment. If you are elderly, your doctor may increase the dose more slowly. Your doctor will then adjust the dose until you reach the dose that is right for you. Some patients may take up to 24 mg of AROPILO SR once daily.
If you experience side effects that are difficult to tolerate at the start of treatment, you should inform your doctor. Your doctor may recommend changing your treatment to a lower dose of ropinirol in the form of immediate-release tablets, which you will take three times a day.
It may take several weeks for the medicine to start working.
Your doctor will determine the dose of AROPILO SR based on the dose of ropinirol immediate-release tablets you were taking previously.
You should take the same dose of ropinirol immediate-release tablets on the day before switching to AROPILO SR. The next morning, you should take AROPILO SR and not take any more ropinirol immediate-release tablets.
You should contact your doctor or pharmacist immediately. If possible, you should show them the AROPILO SR packaging.
If you take more AROPILO SR than you should, you may experience: nausea, vomiting, dizziness, drowsiness, mental fatigue or physical fatigue, fainting, or hallucinations.
If you miss a dose for a day or longer, you should consult your doctor about restarting treatment with AROPILO SR.
You should keep taking AROPILO SR for as long as your doctor recommends. Do not stop taking it unless your doctor tells you to.
If you suddenly stop taking AROPILO SR, your Parkinson's symptoms may quickly get much worse. Stopping treatment suddenly can also cause a serious problem called neuroleptic malignant syndrome, which can be life-threatening. Symptoms include: akinesia (loss of movement), muscle stiffness, fever, unstable blood pressure, rapid heartbeat, confusion, and decreased consciousness (e.g. coma).
If your doctor needs to stop your treatment with AROPILO SR, they will reduce your dose gradually.
If you have any further questions about taking this medicine, you should ask your doctor or pharmacist.
Like all medicines, AROPILO SR can cause side effects, although not everybody gets them.
Ropinirole side effects are most likely to happen when you first start taking the medicine or when your dose is increased. The side effects are usually mild and become less troublesome after taking the medicine for a short time. If you are concerned about side effects, you should talk to your doctor.
May affect more than 1 in 10 peopletaking ropinirole:
fainting
drowsiness
nausea
May affect up to 1 in 10 peopletaking ropinirole
May affect up to 1 in 100 peopletaking ropinirole
allergic reactionssuch as red, itchy swelling of the skin(hives), swelling of the face, lips, mouth, tongue, or throat, which may cause difficulty swallowing or breathing, rash, or intense itching(see section 2).
liver function changes, which have been seen in blood tests.
In patients taking AROPILO SR with L-dopa, the following side effects may also occur:
If you experience any side effects, including those not listed in this leaflet, you should inform your doctor or pharmacist. You can also report side effects directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Jerozolimskie Avenue 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
You can also report side effects to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging after 'EXP'. The expiry date refers to the last day of that month.
Do not store above 30°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
AROPILO SR, 2 mg, prolonged-release tablets:
Pink, speckled, oval tablets, 16 mm x 8.2 mm, with the imprint 2x on one side.
AROPILO SR, 4 mg, prolonged-release tablets:
Brown, speckled, oval tablets, 16 mm x 8.2 mm, with the imprint 4x on one side.
AROPILO SR, 8 mg, prolonged-release tablets:
Dark pink, speckled, oval tablets, 16 mm x 8.2 mm, with the imprint 8x on one side.
Pack sizes:
AROPILO SR, prolonged-release tablets are available in blister packs of 21, 28, 30, 42, 56, 84, or 90 prolonged-release tablets.
Marketing authorization holder
Vipharm S.A.
A. and F. Radziwiłłów Street 9
05-850 Ożarów Mazowiecki
Manufacturer
Actavis Ltd.
BLB 016 Bulebel Industrial Estate
Zejtun ZTN 3000
Malta
Denmark
Aropilo SR
Czech Republic
Aropilos
Poland
AROPILO SR
Slovakia
Aropilos
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.